OnKure Therapeutics, Inc. Class A Common Stock (OKUR)

• Market cap: $38.8M
• 1 day: -7.02%
• 5 days: -10.17%
• 1 month: 44.02%
• 3 months: -42.64%
• 6 months: -73.12%
• Year to date: -68.90%
• 1 year: 55.88%
• 5 years: -80.92%
• 10 years: -80.92%
• Sector: Healthcare
• Industry: Biotechnology

About: OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.

Employees: 46

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

15% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 13

0.1% more ownership

Funds ownership: 93.59% [Q4 2024] → 93.69% (+0.1%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]

8% less funds holding

Funds holding: 51 [Q4 2024] → 47 (-4) [Q1 2025]

49% less capital invested

Capital invested by funds: $99.2M [Q4 2024] → $50.1M (-$49.1M) [Q1 2025]

50% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 8

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $34 1,183% upside
• Avg. target: $34 1,183% upside
• High target: $34 1,183% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Robert Burns

1,183% upside $34

Buy Maintained

18 Mar 2025